Cargando…
Implementation of genotype-guided dosing of warfarin with point-of-care genetic testing in three UK clinics: a matched cohort study
BACKGROUND: Warfarin is a widely used oral anticoagulant. Determining the correct dose required to maintain the international normalised ratio (INR) within a therapeutic range can be challenging. In a previous trial, we showed that a dosing algorithm incorporating point-of-care genotyping informatio...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6454722/ https://www.ncbi.nlm.nih.gov/pubmed/30961588 http://dx.doi.org/10.1186/s12916-019-1308-7 |
_version_ | 1783409596577087488 |
---|---|
author | Jorgensen, Andrea L. Prince, Clare Fitzgerald, Gail Hanson, Anita Downing, Jennifer Reynolds, Julia Zhang, J. Eunice Alfirevic, Ana Pirmohamed, Munir |
author_facet | Jorgensen, Andrea L. Prince, Clare Fitzgerald, Gail Hanson, Anita Downing, Jennifer Reynolds, Julia Zhang, J. Eunice Alfirevic, Ana Pirmohamed, Munir |
author_sort | Jorgensen, Andrea L. |
collection | PubMed |
description | BACKGROUND: Warfarin is a widely used oral anticoagulant. Determining the correct dose required to maintain the international normalised ratio (INR) within a therapeutic range can be challenging. In a previous trial, we showed that a dosing algorithm incorporating point-of-care genotyping information (‘POCT-GGD’ approach) led to improved anticoagulation control. To determine whether this approach could translate into clinical practice, we undertook an implementation project using a matched cohort design. METHODS: At three clinics (implementation group; n = 119), initial doses were calculated using the POCT-GGD approach; at another three matched clinics (control group; n = 93), patients were dosed according to the clinic’s routine practice. We also utilised data on 640 patients obtained from routinely collected data at comparable clinics. Primary outcome was percentage time in target INR range. Patients and staff from the implementation group also provided questionnaire feedback on POCT-GGD. RESULTS: Mean percentage time in INR target range was 55.25% in the control group and 62.74% in the implementation group; therefore, 7.49% (95% CI 3.41–11.57%) higher in the implementation group (p = 0.0004). Overall, patients and staff viewed POCT-GGD positively, suggesting minor adjustments to allow smooth implementation into practice. CONCLUSIONS: In the first demonstration of the implementation of genotype-guided dosing, we show that warfarin dosing determined using an algorithm incorporating genetic and clinical factors can be implemented smoothly into clinic, to ensure target INR range is reached sooner and maintained. The findings are like our previous randomised controlled trial, providing an alternative method for improving the risk-benefit of warfarin use in daily practice. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12916-019-1308-7) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6454722 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-64547222019-04-19 Implementation of genotype-guided dosing of warfarin with point-of-care genetic testing in three UK clinics: a matched cohort study Jorgensen, Andrea L. Prince, Clare Fitzgerald, Gail Hanson, Anita Downing, Jennifer Reynolds, Julia Zhang, J. Eunice Alfirevic, Ana Pirmohamed, Munir BMC Med Research Article BACKGROUND: Warfarin is a widely used oral anticoagulant. Determining the correct dose required to maintain the international normalised ratio (INR) within a therapeutic range can be challenging. In a previous trial, we showed that a dosing algorithm incorporating point-of-care genotyping information (‘POCT-GGD’ approach) led to improved anticoagulation control. To determine whether this approach could translate into clinical practice, we undertook an implementation project using a matched cohort design. METHODS: At three clinics (implementation group; n = 119), initial doses were calculated using the POCT-GGD approach; at another three matched clinics (control group; n = 93), patients were dosed according to the clinic’s routine practice. We also utilised data on 640 patients obtained from routinely collected data at comparable clinics. Primary outcome was percentage time in target INR range. Patients and staff from the implementation group also provided questionnaire feedback on POCT-GGD. RESULTS: Mean percentage time in INR target range was 55.25% in the control group and 62.74% in the implementation group; therefore, 7.49% (95% CI 3.41–11.57%) higher in the implementation group (p = 0.0004). Overall, patients and staff viewed POCT-GGD positively, suggesting minor adjustments to allow smooth implementation into practice. CONCLUSIONS: In the first demonstration of the implementation of genotype-guided dosing, we show that warfarin dosing determined using an algorithm incorporating genetic and clinical factors can be implemented smoothly into clinic, to ensure target INR range is reached sooner and maintained. The findings are like our previous randomised controlled trial, providing an alternative method for improving the risk-benefit of warfarin use in daily practice. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12916-019-1308-7) contains supplementary material, which is available to authorized users. BioMed Central 2019-04-08 /pmc/articles/PMC6454722/ /pubmed/30961588 http://dx.doi.org/10.1186/s12916-019-1308-7 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Jorgensen, Andrea L. Prince, Clare Fitzgerald, Gail Hanson, Anita Downing, Jennifer Reynolds, Julia Zhang, J. Eunice Alfirevic, Ana Pirmohamed, Munir Implementation of genotype-guided dosing of warfarin with point-of-care genetic testing in three UK clinics: a matched cohort study |
title | Implementation of genotype-guided dosing of warfarin with point-of-care genetic testing in three UK clinics: a matched cohort study |
title_full | Implementation of genotype-guided dosing of warfarin with point-of-care genetic testing in three UK clinics: a matched cohort study |
title_fullStr | Implementation of genotype-guided dosing of warfarin with point-of-care genetic testing in three UK clinics: a matched cohort study |
title_full_unstemmed | Implementation of genotype-guided dosing of warfarin with point-of-care genetic testing in three UK clinics: a matched cohort study |
title_short | Implementation of genotype-guided dosing of warfarin with point-of-care genetic testing in three UK clinics: a matched cohort study |
title_sort | implementation of genotype-guided dosing of warfarin with point-of-care genetic testing in three uk clinics: a matched cohort study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6454722/ https://www.ncbi.nlm.nih.gov/pubmed/30961588 http://dx.doi.org/10.1186/s12916-019-1308-7 |
work_keys_str_mv | AT jorgensenandreal implementationofgenotypeguideddosingofwarfarinwithpointofcaregenetictestinginthreeukclinicsamatchedcohortstudy AT princeclare implementationofgenotypeguideddosingofwarfarinwithpointofcaregenetictestinginthreeukclinicsamatchedcohortstudy AT fitzgeraldgail implementationofgenotypeguideddosingofwarfarinwithpointofcaregenetictestinginthreeukclinicsamatchedcohortstudy AT hansonanita implementationofgenotypeguideddosingofwarfarinwithpointofcaregenetictestinginthreeukclinicsamatchedcohortstudy AT downingjennifer implementationofgenotypeguideddosingofwarfarinwithpointofcaregenetictestinginthreeukclinicsamatchedcohortstudy AT reynoldsjulia implementationofgenotypeguideddosingofwarfarinwithpointofcaregenetictestinginthreeukclinicsamatchedcohortstudy AT zhangjeunice implementationofgenotypeguideddosingofwarfarinwithpointofcaregenetictestinginthreeukclinicsamatchedcohortstudy AT alfirevicana implementationofgenotypeguideddosingofwarfarinwithpointofcaregenetictestinginthreeukclinicsamatchedcohortstudy AT pirmohamedmunir implementationofgenotypeguideddosingofwarfarinwithpointofcaregenetictestinginthreeukclinicsamatchedcohortstudy |